Zealand Pharma A/S
$919.9K 108 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aesculap, Inc.
Aesculap, Inc. reported $921,524.18 across General Payments, Research, and Ownership to 705 physicians and teaching hospitals across 705 transactions.
- $921.5K Above-median payer
- All-tracks total
- 705 Above-median volume
- Transactions
- 705 Above-median reach
- Recipients
- +$378.1K
- General Payments vs PY2023
Aesculap, Inc. reported $921,524.18 across all CMS Open Payments tracks (General + Research + Ownership) to 705 physicians and teaching hospitals in Program Year 2024 - ranking #639 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $921,524.18, averaging $1.3K per recipient.
Aesculap, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
28/100
Total payments
F
18/100
Transaction volume
F
15/100
Physician reach
F
15/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aesculap-inc Aesculap, Inc.
$921.5K · #639/1,925 · 0.0% industry · PY2024
- TOT $921.5K
- RANK #639
- SHARE 0.0%
- TXN 705
- RCP 705
- CAT 5
- GEN $921.5K
- ΔGEN +$378.1K
- TOP1 20.6%
- PY 2024
Volume peers
Nearest volume peer: Zealand Pharma A/S ($919.9K)
Aesculap, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aesculap, Inc.'s CMS-reported General Payments increased by $378.1K (+69.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AESCULAP, INC.PY2023: AESCULAP, INC.PY2024: Aesculap, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $543,388.19
- PY2024
- $921,524.18
What the Data Shows for Aesculap, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Aesculap, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
107 transactions worth $706.0K make "Debt Forgiveness" the top general-payment category in the 5-category breakdown below, 76.6% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Debt Forgiveness" leads Aesculap, Inc.'s 5-category general-payment breakdown at $706.0K, 76.6% of the reported total.
Aesculap, Inc. reports 5 general-payment categories - the top three are Debt Forgiveness (76.6%), Consulting Fee (17.2%), and Food and Beverage (2.5%). The remaining 2 categories make up 3.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Aesculap, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Debt Forgiveness | $706.0K | 107 | 76.6% |
| Consulting Fee | $158.3K | 15 | 17.2% |
| Food and Beverage | $22.7K | 465 | 2.5% |
| Travel and Lodging | $21.5K | 115 | 2.3% |
| Space Rental or Facility Fees | $13.0K | 3 | 1.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $386,562.51 (41.9%) of $921,524.18 in this company's General Payments records across 406 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aesculap, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Hoboken University Medical Center
$189,786.61 across 1 reported transactions
- 2
Medical Center Health System
$62,456.81 across 2 reported transactions
- 3
Steward Holy Family Hospital
$58,079.37 across 1 reported transactions
- 4
St Joseph Medical Center
$41,739.72 across 1 reported transactions
- 5
Kfh - Downey
$34,500.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aesculap, Inc. ranks #639 of 1,925 by total payments (top 33% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,213 of 1,838 by HHI (bottom 34% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- BioMarin Pharmaceutical Inc. : $3.0M total payments, HHI 639
- Roche Molecular Systems, Inc. : $3.5M total payments, HHI 638
- Aroa Biosurgery Incorporated : $591.0K total payments, HHI 637
- Napo Pharmaceuticals Inc : $189.6K total payments, HHI 636
- Arthrosurface Incorporated : $1.8K total payments, HHI 636
- B. Braun Interventional Systems Inc. : $271.8K total payments, HHI 635
- Aesculap, Inc. (this company) : $921.5K total payments, HHI 634
- Ultragenyx Pharmaceutical Inc. : $454.6K total payments, HHI 634
- Pulmonx Corporation : $847.7K total payments, HHI 633
- SurGenTec : $704.8K total payments, HHI 632
- Zak Ortho : $11.4K total payments, HHI 631
- Bio-Rad Laboratories, Inc. : $421.2K total payments, HHI 631
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aesculap, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aesculap, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aesculap, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
ImmunoGen, Inc.
$919.6K 430 recipients
Compare payment profiles
Spineology Inc.
$923.8K 1,284 recipients
Compare payment profiles
Cumberland Pharmaceuticals, Inc.
$918.2K 3,940 recipients
Compare payment profiles
Access Vascular Inc
$914.0K 47 recipients
Compare payment profiles
Rapid Medical Ltd
$930.1K 670 recipients
Compare payment profiles
Put this to use
Aesculap, Inc. ranks #639 of 1,925 by all-tracks total payments, led by "Debt Forgiveness".
- See where Aesculap, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Debt Forgiveness" spend across every manufacturer, not just Aesculap, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.